Carl Zeiss Meditec AG (XETR: AFX) — The Moat Survived; Returns Must Recover

Published: 2026-09-12 · Verdict: Watch · Research confidence: High (90%)

Executive conclusion

Analyst Take

Carl Zeiss Meditec merits a WATCH. The company owns differentiated assets—VISUMAX/SMILE, a broad diagnostic installed base, leading surgical microscopes and a more complete retinal-surgery platform after DORC—but those assets are not currently producing an adequate return on the capital committed to them. The central tension is unusually stark: the technical moat appears substantially intact, while the financial evidence that should validate that moat has deteriorated.

Revenue increased from €1.647 billion in FY2020/21 to €2.228 billion in FY2024/25, a 7.8% compound rate, yet EBIT fell from €373.6 million to €223.3 million and the EBIT margin contracted from 22.7% to 10.0%. The company’s EVA framework reported negative €55.4 million for FY2024/25 after the DORC acquisition nearly doubled gross capital employed. Nine-month FY2025/26 adjusted EBITA then declined 29.7% to €124.5 million, or 8.0% of sales, despite broadly stable revenue after management’s currency and China-channel adjustments. These are reported facts; the conclusion that the company’s moat is being poorly monetized is analytical inference. [S1][S2][S15]

The bear case is stronger than a routine cyclical explanation. China contributes about 23% of revenue and combines centralized IOL procurement, a withdrawn bifocal lens, weak refractive procedures, cautious equipment spending, currency pressure and emerging domestic competitors. DORC cost €1.024 billion and added €581.6 million of goodwill, while overlapping platforms and sites are now being eliminated. The issuer also spent €150.1 million repurchasing shares at an average €78.76 shortly before earnings deteriorated. A projected goodwill impairment of approximately €150 million is noncash, but it confirms that expected cash flows attached to prior investment have fallen materially. [S1][S2][S3][S15]

The bull case is that the market is extrapolating a period of operational disorder into permanent franchise impairment. Approximately 51% of nine-month revenue was recurring or procedure-linked, the order backlog was €432 million, leverage remained modest, and SMILE’s treatment packs and licenses have genuine platform-specific characteristics. ProfitUp targets more than €200 million of annual gross improvement by FY2028/29 and more than €160 million after roughly €40 million of additional infrastructure costs. On the current revenue base, that net target is arithmetically large enough to restore a mid-teens margin. Parent and insider purchases add a favorable signal, although the parent program does not retire shares and is not a valuation floor. [S1][S3][S5][S6][S10][S11][S12][S17]

At the 11 September 2026 Xetra close of €30.30, economically outstanding equity is worth approximately €2.65 billion. Adding June net financial debt of €234.8 million gives simplified enterprise value near €2.89 billion; adding the latest fully disclosed €132.5 million of lease liabilities produces a lease-adjusted figure near €3.02 billion before small minority interests. Against management’s €172–220 million FY2025/26 adjusted-EBITA range, those figures imply approximately 13.1–16.8 times and 13.8–17.6 times, respectively. That is cheaper than Alcon on sales but not obviously distressed for a business with negative EVA and repeated forecast resets. [S1][S2][S23]

The scenario-weighted outcome is close to the current quotation. Discounted FY2028/29 values are approximately €15 in a persistent-impairment case, €37 in a partial-repair case and €56 in a successful-restructuring case. Below roughly €24, the relationship between the base and bear cases would become more attractive; at €30.30, proof of execution is still worth more than the optionality of anticipating it. These are analyst estimates, not company guidance.

Investment conviction is moderate. Evidence quality is high for reported financials, DORC consideration, the repurchase, the restructuring envelope and current China weakness. It is only moderate for future savings, product conversion, DORC synergies and terminal margins. The near-term decision sequence is the FY2025/26 result and final impairment, the next China IOL procurement round, the permanent CEO’s start, disclosed ProfitUp cash costs, FY2026/27 guidance, recurring gross-profit development and DORC/EVA NEXUS economics. The call would improve with organic growth above 5%, adjusted EBITA above 12%, conventional free cash flow covering restructuring and dividends, and positive EVA. It would deteriorate with another guidance withdrawal, China price pressure spreading to SMILE packs, restructuring costs exceeding €150 million, or new major M&A before existing capital earns its charge.

Stock Price Action — Five-Year Event Map

The five-year chart is a valuation reset accompanied by a real earnings reset. Xetra closed at €199.05 on 21 September 2021, the highest close in the five-year window, and at €23.42 on 23 March 2026, the lowest. The 11 September 2026 close was €30.30: 84.8% below the peak, 29.4% above the trough, 36.5% below the 52-week closing high of €47.72 and 29.4% above the 52-week low. From 10 September 2021, compound price performance was approximately negative 31.2% annually and annualized daily volatility approximately 42%. Those statistics are calculated from daily Xetra prices; explanations assigned to individual moves are interpretations, not mechanical attribution. [S23]

The pattern matters. The worst daily move was the 20.5% decline on the June 2024 guidance cut; the January 2026 warning produced another 16.6% decline. The largest 2026 up-days followed ProfitUp and the parent purchase announcement. This supports an inference that recent marginal price discovery has been highly sensitive to company-specific forecast revisions and capital-allocation signals. It does not prove that broad healthcare, European small-cap, currency, rate or momentum factors were immaterial.

The factor model snapshot was unavailable. Consequently, no statistical beta, style exposure, alpha or residual return can responsibly be stated. Absence of a model observation is not evidence of zero factor exposure. AFX is likely exposed economically to European equity risk, healthcare capital spending and EUR/CNY and EUR/USD translation, but those are fundamental sensitivities rather than measured factor-model coefficients. [S1][S2]

The distance from the peak is therefore not a valuation argument. Between the 2021 high and September 2026, the EBIT margin more than halved, invested capital increased materially and forecast credibility deteriorated. Mean reversion in price requires mean reversion in cash returns, not merely survival of the corporate franchise.

Verdict: The old premium has been removed, but the drawdown largely coincided with genuine deterioration in margins, EVA and execution. The tape shows restructuring optionality; it does not yet show verified operating repair.

Business Overview

Carl Zeiss Meditec is a German medical-technology company controlled by Carl Zeiss AG. It reports two strategic business units. Ophthalmology generated €1.724 billion, or 77.4% of FY2024/25 revenue; Microsurgery generated €503.9 million, or 22.6%. The company develops diagnostic, visualization and surgical systems, intraocular lenses, refractive-laser treatment packs and licenses, surgical consumables, instruments, service and digital-workflow products. It uses the broader ZEISS organization’s commercial and service network while maintaining production and development operations across Europe, the United States and Asia. [S2]

The core economics are understandable through equipment, consumables and service: equipment creates an installed base, procedures monetize it, and service protects uptime and the customer relationship. Equipment includes OCT and fundus-imaging systems, visual-field devices, optical biometers, refractive lasers, phaco and vitreoretinal consoles and surgical microscopes. These sales are transactional and sensitive to replacement cycles, customer financing, tenders, hospital budgets and regulatory launch timing. A large system sale creates near-term revenue but is valuable only if it establishes future procedure or service economics.

Consumables are heterogeneous. A SMILE procedure requires a sterile, single-use treatment pack approved for the platform and a treatment license provided under a commercial agreement. That is a comparatively strong razor-and-blade mechanism. DORC’s cassettes, cutters, fluids, dyes and instruments can recur with retinal procedures, although rival surgical ecosystems compete for the installed platform. IOLs recur with cataract procedures but are implants that can be substituted through tenders or surgeon preference. Calling all three streams recurring without distinguishing their mechanisms would overstate revenue durability. [S1][S3][S17]

At nine months FY2025/26, management’s product split was approximately 49% equipment, 41% consumables and 10% service. Ophthalmology was about 41% equipment, 50% consumables and 9% service; Microsurgery was approximately 78% equipment, 8% consumables and 14% service. The company classified 50.9% of group revenue as recurring, down from 51.9% a year earlier. Approximately half of group revenue is recurring or procedure-linked, but stability varies materially: proprietary packs and licenses have the strongest attachment, IOLs remain tender-exposed, service is only 10% of sales, and Microsurgery is predominantly capital equipment. [S1][S3]

That mix explains both resilience and operating volatility. The recurring portion reduces dependence on a single capital cycle, but it cannot protect profit when high-margin China IOL or refractive revenue disappears. The equipment portion is also economically linked to the recurring portion: reduced placements today can weaken consumable growth years later. A useful model therefore tracks installed systems, utilization per system, consumable price, service attachment and replacement rates rather than applying one recurrence multiple to consolidated sales.

Ophthalmology spans diagnosis and treatment. Diagnostics include CIRRUS OCT, CLARUS fundus imaging, optical biometry, perimetry and related software. Refractive surgery centers on VISUMAX and SMILE. Cataract and retinal surgery include IOLs, phacoemulsification, vitrectomy systems and consumables, expanded materially through DORC. This breadth can reduce manual data transfer and support connected planning, but breadth also creates duplicated development programs, regulatory obligations and manufacturing infrastructure.

Microsurgery supplies visualization systems for neurosurgery, spine, ENT and other microsurgical procedures. Its commercial strength is optical quality, surgeon familiarity, robotic positioning, fluorescence and workflow integration. Its weakness as a financial model is the lack of a large proprietary consumables stream. Long replacement cycles can protect installed share but make annual revenue depend on a relatively small number of high-value orders.

Geographic concentration is material. FY2024/25 revenue was €991.0 million from APAC, €657.5 million from EMEA and €579.2 million from the Americas. APAC therefore represented 44.5%. At nine months FY2025/26, APAC was approximately 41.7%, and management said China represented about 23% of group revenue. EMEA grew in the latest period, the Americas improved after currency adjustment, and APAC declined 8.7% reported. The portfolio is globally diversified, but its profit exposure is less diversified than revenue because China has historically contained important premium lenses and refractive consumables. [S1][S2][S3]

The wider ZEISS relationship is an operating asset and a governance dependency. The group benefits from more than 60 sales and service locations and more than 30 production sites in the broader network. FY2024/25 sales of merchandise to related companies totaled approximately €1.177 billion. Related parties also provided services, treasury functions, financing, R&D and property. Those relationships can create scale that a stand-alone competitor would struggle to replicate; they also make transfer pricing, service charges and minority-shareholder governance more important. [S2][S9]

The installed base, procedure licenses, surgeon training, diagnostic data continuity, regulatory approvals, service coverage, optical know-how and more than 1,000 patent families are economically valuable assets not fully recognized on the balance sheet. Their value should appear in retention, price, service revenue, product adoption and returns on development spending. Patent counts alone are insufficient: the annual report acknowledges that patents often protect particular product features rather than an entire mature product’s basic functionality. [S2]

The acquired assets are much more visible. At September 2025, goodwill was €969.7 million and other intangible assets €662.9 million, together approximately 48% of total assets and 77% of equity. The balance sheet therefore understates internally generated franchise value while prominently carrying acquisition risk. Book value is neither a complete measure of the moat nor a conservative floor.

DORC added vitreoretinal systems and procedure-linked products. The strategic rationale is coherent: connect diagnostics, planning, visualization, consoles and consumables while offering a broader alternative to Alcon. The subsequent decisions to sunset QUATERA, consolidate anterior and posterior surgery, wind down overlapping Katalyst activities and focus on EVA NEXUS demonstrate that the pre-existing and acquired portfolios contained meaningful duplication. Those actions may improve future economics, but they contradict any claim that integration was frictionless. [S3][S5][S15]

Customer value comes from clinical performance, workflow efficiency and reliability. Accurate diagnostics can improve treatment planning; faster refractive platforms can raise clinic throughput; integrated retinal systems can reduce operating-room complexity; reliable microscopes can support precise surgery. The company captures value through initial hardware margins, procedure-linked consumables, software, service and replacement sales. Whether it retains that value depends on product quality, regulatory continuity and customer willingness to remain on the platform.

AFX is a German no-par-value bearer ordinary share listed on Xetra, not an ADR, partnership, MLP or K-1 issuer. Carl Zeiss AG held approximately 59.1% of issued shares at the FY2024/25 reporting date, treasury shares represented 2.1%, and free float approximately 38.7%. Investors face the ordinary tax and withholding considerations applicable to German shares and their own jurisdictions; this report does not provide individual tax advice. [S2]

Verdict: The business is understandable and owns valuable installed-base assets, but it is not a uniform annuity. SMILE offers the clearest proprietary consumables mechanism; IOLs are procurement-sensitive, diagnostics are interoperable, and Microsurgery remains equipment-heavy.

Industry Dynamics

Carl Zeiss Meditec participates in global ophthalmic diagnosis, ophthalmic surgery, refractive correction and surgical visualization. Its own market estimates place directly relevant ophthalmology submarkets at approximately US$15.3 billion in calendar 2024 and its relevant surgical-microscope market at approximately US$0.8 billion. The company estimates an ophthalmology share near 11%, ranking second, and a microscope share above 50%, ranking first. These are management estimates based on selected market definitions, not audited market shares. [S2]

Alcon independently estimates the surgical market in which it participates at approximately US$14 billion and expects 4–6% annual growth from 2025 through 2030. The definitions are not identical—Alcon includes its own implantables, consumables, equipment and related support—but the figures corroborate the order of magnitude and low- to mid-single-digit structural growth assumption. Alcon’s 2025 Surgical revenue was US$5.751 billion, including US$3.028 billion of consumables, US$1.782 billion of implantables and US$941 million of equipment and other revenue. [S18]

The addressable markets are global and structurally growing at roughly low- to mid-single-digit rates, while demand for Carl Zeiss Meditec is unusually international: APAC produced 44.5% of FY2024/25 revenue and China about 23% at nine months FY2025/26. [S1][S2][S18]

Demand benefits from aging, cataract procedures, retinal disease, myopia, higher healthcare access and premium patient-pay offerings. WHO reported that cataract risk rises with age, that cataract treatment involves surgery and IOL implantation, and that maintaining current service coverage would require millions of additional annual procedures. WHO also projected the number of people with myopia to rise from 1.95 billion in 2010 to 3.36 billion in 2030. These are strong volume tailwinds, but they do not determine supplier pricing or capital returns. [S21]

The supply side is concentrated within individual categories but fragmented across the full workflow. Alcon is the largest integrated ophthalmic-surgical competitor. Bausch + Lomb, Johnson & Johnson Vision, Hoya and other lens or surgical specialists compete in cataract. Topcon, Heidelberg Engineering, Optos/Nikon and Nidek compete in diagnostics. Leica Microsystems is the closest large microscope rival. Johnson & Johnson, SCHWIND, Ziemer and implantable-lens alternatives compete in refractive correction. A customer can therefore source an integrated suite or assemble a multi-vendor environment.

Industry profitability is protected by regulatory approvals, optical and software expertise, installed platforms, clinical evidence, surgeon training, field service and the cost of supporting a global portfolio; nevertheless, several well-capitalized competitors contest every important profit pool. Alcon’s 2025 Surgical revenue was more than three times Carl Zeiss Meditec’s Ophthalmology revenue, and Alcon describes the industry’s largest installed base of operating-room equipment. Scale supports submissions, service density, bundled contracting and R&D. Carl Zeiss Meditec counters with diagnostic breadth, refractive differentiation and microscopy leadership, but does not enjoy Alcon’s surgical scale. [S2][S18]

Regulation is a barrier and a discontinuity risk. High-risk lasers, lenses and surgical systems require clinical evidence, quality systems and country-specific approvals. Those requirements slow a new entrant and protect existing platforms, but they can also strand inventory or delay a successor product. The China bifocal-lens withdrawal illustrates that registration alone is not sufficient: the successor requires both approval and procurement access before meaningful commercialization.

The capital cycle is less attractive than the demand cycle. Surgical and diagnostic equipment can remain in service for years, so replacement demand is lumpy. Suppliers may accept lower equipment economics to secure later consumable or service revenue. A platform transition can create both a replacement opportunity and an installed-base risk. Fixed R&D, regulatory and field-service costs then cause profits to fall faster than revenue when equipment or premium-product mix weakens. Nine-month FY2025/26 revenue declined 2.9%, but adjusted EBITA fell 29.7%, a direct example of that operating leverage. [S1]

Competition is intensifying in integrated surgical platforms. Alcon introduced UNITY VCS in 2025 as the successor to Constellation and began introducing UNITY CS for cataract surgery. Bausch + Lomb’s Surgical business already derives 52% of segment revenue from consumables, 24% from implantables and 24% from equipment, demonstrating that competitors also pursue installed-base monetization. Its 2025 surgical profit was hurt materially by an IOL recall, showing that product quality can overwhelm otherwise recurring revenue. [S18][S19]

Digital integration is another contested layer. ZEISS diagnostic and planning products can improve workflow and reinforce customer relationships. However, Topcon markets Harmony as vendor-inclusive and able to connect multiple brands and devices. Interoperability expands the software opportunity while limiting the credibility of a fully closed-system thesis. Data continuity creates friction, but standards and migration tools prevent absolute captivity. [S20]

China changes the profit pool through procurement rather than merely lower unit manufacturing cost. China’s National Healthcare Security Administration reported that the fourth national high-value-consumables procurement round reduced average IOL prices by approximately 60%, with different reductions by category. Carl Zeiss Meditec withdrew an existing bifocal product, accepted returns and write-offs and lost high-margin revenue while awaiting the next tender for its successor. Management also expects more domestic premium-IOL competitors. [S1][S3][S22]

Refractive surgery differs because treatment packs and licenses attach to the VISUMAX platform and elective procedures are not currently governed like public cataract implants. Management said no material treatment-pack price pressure was visible at the August call, but that statement is a management observation, not independent evidence. Procedure growth weakened in June and July, and management expects a domestic refractive competitor. China can therefore damage the franchise through lower utilization and new placements even without formal pack procurement. [S3][S17]

Competitive intensity is rising in China and integrated surgical platforms even though the total market continues to grow; new platform generations, localized entrants and centralized purchasing raise the cost of defending share. [S3][S18][S19][S22]

Foreign low-cost production is not sufficient by itself to replicate the business. Optics, software, regulatory approvals, clinical support and service matter more than assembly wages. But localization is financially material. A Chinese manufacturer can win access or price without matching every global feature, while Carl Zeiss Meditec’s planned India capacity and larger China footprint show that regional cost and procurement eligibility are becoming competitive requirements. Localized foreign competitors can undermine pricing and access without reproducing the whole portfolio; labor cost is not the moat, but local manufacturing, registration speed and procurement status can change the economics. [S3][S5]

The industry can remain profitable if procedure volume grows, premium innovation earns reimbursement or patient-pay pricing, and proprietary consumables remain attached. It can become less profitable when suppliers overinvest in overlapping platforms, subsidize placements, suffer recalls or encounter centralized procurement. Secular demand growth is therefore necessary but not sufficient for an attractive equity return.

Verdict: Eye-care demand is structurally favorable and barriers are meaningful, but the supply-side capital cycle is becoming more demanding. Scale, platform refreshes and China procurement currently favor disciplined integrated operators over companies carrying duplicated portfolios.

Competitive Position

Carl Zeiss Meditec’s competitive position must be assessed product by product. Aggregate management-estimated shares—approximately 11% in relevant ophthalmology and more than 50% in surgical microscopes—establish relevance, not uniform pricing power. The relevant test is whether a specific barrier produces measurable retention, price, gross margin and return on capital.

The clearest moat mechanism is VISUMAX/SMILE. FDA professional-use information states that SMILE requires activation through a treatment license provided by Carl Zeiss Meditec or an authorized representative. It also specifies that treatment packs are single-use, cannot be resterilized and must be expressly approved for the system. Surgeon training and service add further friction. Switching costs are highest in VISUMAX/SMILE, where proprietary single-use packs, procedure licenses, training and service bind recurring revenue to an approved capital platform. [S17]

That mechanism should create four observable outcomes: stable pack pricing, increasing procedures per installed system, high service attachment and resistance to competing platform placements. If those outcomes deteriorate after local Chinese or multinational lenticule systems enter, the moat is weaker than the regulatory and physical linkage suggests. Proprietary consumables protect only procedures performed on the installed base; they do not guarantee that clinics will buy the next platform generation.

DORC’s EVA NEXUS has moderate-to-high switching friction. Vitreoretinal and cataract consoles generate cassettes, cutters, fluids, dyes, tips and other procedure products. Operating-room training and service reliability matter. Yet Alcon’s UNITY platform and Bausch + Lomb’s installed systems offer alternative ecosystems at replacement. The choice to retire QUATERA and concentrate investment on EVA NEXUS recognizes the importance of platform scale while also admitting that Carl Zeiss Meditec could not efficiently support every overlapping platform. [S3][S18][S19]

Diagnostics have moderate switching costs. Longitudinal patient data, staff training, device connectivity and planning interfaces make replacement inconvenient. The moat is strongest where measurement algorithms or planning tools demonstrably improve outcomes. It is weaker where customers can export data, connect third-party equipment or substitute another imaging system. Topcon’s explicitly vendor-inclusive Harmony architecture is disconfirming evidence against describing digital workflow as a closed walled garden. [S20]

IOL switching costs are low to moderate. Clinical outcomes, lens constants, injector systems, surgeon familiarity and premium designs matter, but multiple approved implants can be used with common diagnostic and surgical workflows. The China procurement episode is decisive counterevidence to an unqualified brand moat: a tender and product withdrawal interrupted revenue despite the ZEISS name. Premium private-pay lenses may retain differentiation; centralized buyers can still redistribute margin.

Surgical microscopes benefit from optical performance, ergonomics, reliability, fluorescence, robotic positioning, surgeon familiarity and service. Long replacement cycles and a company-estimated share above 50% support durability. The segment’s economics nonetheless remain equipment-heavy. There is no SMILE-like mandatory consumable stream, and Leica offers credible high-end alternatives. Microsurgery’s EBITA margin fell from 20.0% in FY2023/24 to 14.0% in FY2024/25 despite claimed leadership. That is important disconfirming evidence: leading share did not prevent margin compression. [S1][S2]

Brand matters because customers use the products in sight-critical and complex procedures. The ZEISS name can reduce perceived clinical risk, support training adoption and reinforce service trust. It can also help recruitment and global account access. The ZEISS brand matters economically when it shortens adoption, supports price, improves service retention or wins placements; China IOL procurement proves that brand cannot override price and tender access in every channel. [S1][S2][S22]

Competition occurs at workflow and platform level—clinical outcomes, regulatory timing, uptime, consumable attachment, service density, portfolio breadth and price matter more than a single hardware specification. Alcon’s advantage is surgical scale and installed base. Carl Zeiss Meditec’s differentiated combination is diagnostics, refractive lasers and microscopy. Bausch + Lomb and category specialists can attack individual profit pools without replicating the full workflow. [S18][S19]

R&D is a necessary moat input, not an output. FY2024/25 expensed R&D was €326.3 million, or 14.6% of revenue, and approximately 20% of employees worked in R&D. The company also capitalized €34.9 million of development spending. More than 1,000 patent families and country approvals raise replication costs. Conversely, unfinished development assets, impairments and project pruning indicate that some spending failed to generate commercial returns. [S2]

The broader ZEISS network creates a scale advantage in optics, distribution and service, but it also makes the public subsidiary dependent on a controlling related party. In FY2024/25, merchandise sales to related parties exceeded €1.17 billion, and the parent network supplied material services and financing. The economic benefit should be assessed after all related-party charges, not inferred solely from revenue access. [S2][S9]

A genuine group moat should ultimately appear in consolidated economics. Gross margin declined from 58.7% in FY2020/21 to 52.8% in FY2024/25 and 51.0% in nine-month FY2025/26. EBITA and EVA also fell. Those outputs do not prove that every product advantage disappeared; they show that product advantages have not offset procurement, mix, duplication and investment burden at group level.

Verdict: Carl Zeiss Meditec retains genuine advantages, particularly in SMILE and microscopy, but it does not possess a group-wide closed ecosystem. The investment case requires the technical moat to reappear in recurring gross profit and post-investment returns.

Growth History and Forward Opportunities

Reported five-year growth is respectable but acquisition and currency effects matter. Revenue increased from €1.647 billion in FY2020/21 to €1.903 billion in FY2021/22, €2.089 billion in FY2022/23, €2.066 billion in FY2023/24 and €2.228 billion in FY2024/25. The compound rate was 7.8%, but FY2024/25 growth was only 3.3% after currency and acquisition adjustments. Nine-month FY2025/26 revenue fell 2.9% reported. [S1][S2]

The latest disclosure contains a small but important comparability issue. The nine-month headline described currency-adjusted revenue as stable, while the standardized table showed approximately negative 0.7%. Management’s broader adjustment also captures Chinese exports invoiced through the ZEISS network and affected by CNY movements. The formal reported decline of 2.9% should remain the anchor; adjusted measures are useful only with the extra channel treatment disclosed. [S1]

Product opportunities are spread across several platforms. VISUMAX 800 can enlarge and refresh the SMILE installed base. Aier Eye Hospital’s order for 25 systems is evidence of placement demand, but future value depends on activation, utilization and pack economics. EVA NEXUS is becoming the consolidated cataract and vitreoretinal platform. The cataract-only configuration, AT LUCIA toric 721P, Surgery Planner and VISUMAX software updates broaden the workflow. TorUS could add procedure-linked products to KINEVO if cleared and adopted. Company launch materials establish availability or intention, not commercial success, and explicitly note that regulatory status varies by market. [S3][S14]

The product outlook depends on regulatory approvals, installed-base placements and procedure attachment: VISUMAX 800, EVA NEXUS, the successor China bifocal IOL, a US trifocal lens, TorUS and Surgery Planner matter only if they convert into recurring contribution and acceptable returns. [S3][S14]

China is the largest near-term swing factor. The successor bifocal IOL has approval, but management said it cannot meaningfully commercialize until inclusion in the next procurement round. Management expected a tender process in late calendar 2026 and implementation thereafter, but it does not control the schedule, qualification or realized price. The original withdrawal created about €30 million of missing high-margin revenue by management’s estimate. A return of volume at much lower price would not restore the former profit contribution one-for-one. [S1][S3]

Refractive growth in China was slightly positive year to date at the August call, but June and July procedures were below prior-year levels. Twenty-five Aier placements can add capacity; weak utilization could dilute the economic benefit. The model should therefore separate systems shipped, activated systems, procedures per system, treatment-pack price and service revenue.

DORC offers cross-selling and platform-consolidation opportunities. Management expects more meaningful commercial synergies after the current fiscal year. The acquired retinal consumables are strategically attractive, but public reporting does not isolate DORC’s gross profit, cash contribution or capital employed. Revenue synergy should not be capitalized before the company discloses either incremental contribution or group EVA improvement attributable to it. [S3][S15]

Microsurgery’s opportunity is a replacement cycle around KINEVO 900S and potential procedure attachment through TorUS. The segment grew 7.1% after currency adjustment in nine-month FY2025/26, and its EBITA margin improved modestly to 12.7%. This is positive evidence, but the margin remains below FY2023/24 and the segment is still approximately 78% equipment. [S1][S3]

ProfitUp is the largest earnings-growth lever. Management targets more than €200 million of annual gross improvement by FY2028/29 relative to FY2025/26. About €40 million of incremental infrastructure costs—including ERP, CRM, related-party services and Jena rent—reduces the stated net figure to more than €160 million. Up to 1,000 positions may be affected, and cumulative implementation expenses and investment may reach €150 million. Savings are expected to be back-end loaded, with FY2026/27 described as a consolidation year. [S3][S5][S9]

The arithmetic is feasible: €160 million on a €2.2–2.5 billion revenue base equals approximately 640–730 basis points of margin. The economic bridge is not yet established because inflation, stranded costs, service disruption, product exits and reinvestment can consume benefits. Investors should demand separate disclosure of gross savings, infrastructure expense, cash implementation cost and revenue lost from exited products.

Five operating measures would provide better evidence than launch counts: organic revenue excluding acquisitions and currency; new platform placements; procedures and consumables per installed system; recurring gross profit rather than recurring revenue alone; and EVA after restructuring and acquisition capital. Growth that fails those tests may enlarge the company without creating value.

Verdict: The pipeline and cost opportunity are material, but no single launch repairs the earnings base. A credible recovery requires China access, procedure attachment, DORC cross-selling and net cost removal to work together.

Financial Quality

The multiyear record shows a transition from exceptional reported profitability to inadequate economic returns.

Revenue compounded at 7.8%, while EBIT and EPS declined at approximately 12% annually. Gross margin fell 590 basis points and EBIT margin 1,270 basis points. Purchase-price amortization explains part of the EBIT decline, but EBITA margin also fell from 17.2% in FY2022/23 to 11.6% in FY2024/25. [S2][S15]

FY2024/25 revenue increased 7.8%, but organic and currency-adjusted growth was 3.3%. Gross profit was €1.175 billion. EBIT rose to €223.3 million from €194.5 million and EBITA to €257.7 million from €248.9 million. Prior-year comparisons included an approximately €18 million Topcon settlement in EBITA and €44 million of acquisition-liability remeasurement benefits in the financial result. Attributable FY2024/25 profit nevertheless fell 21% to €141.2 million because finance costs and the absence of prior gains outweighed operating improvement. [S2]

The latest period was weaker. Nine-month revenue was €1.554 billion. Gross margin fell 170 basis points to 51.0%. Reported EBITA declined 38.2% to €108.4 million, while adjusted EBITA declined 29.7% to €124.5 million. Ophthalmology EBITA margin collapsed from 10.6% to 5.2%; Microsurgery improved from 12.3% to 12.7%. Management’s FY2025/26 guidance of €2.15–2.20 billion revenue and an 8–10% adjusted-EBITA margin implies €172–220 million of adjusted EBITA. [S1]

Adjustments require scrutiny. The nine-month bridge excluded legal costs, bifocal-IOL inventory scrapping, R&D impairment and ProfitUp expenses. It also removed €11.5 million of tariff refunds attributed to prior periods while retaining the current-period portion. The adjustments help compare operating periods, but scrapped inventory and impaired development are evidence of failed investment. Adjusted EBITA should be analyzed beside reported EBITA and cash flow, not substituted for them.

Earnings are below the prior-cycle peak, but not at a clean cyclical trough: external capital spending and China weakness matter, while product withdrawals, duplicated platforms, acquisition integration and repeated forecast failures show that internal execution also depressed the cycle. [S1][S3][S24]

Return on capital is decisive. The company’s EVA calculation starts with EBIT after a 29.87% group tax rate, adds purchase-price-allocation amortization and subtracts a charge on average gross capital employed. FY2024/25 average gross capital employed was €2.433 billion and the cost-of-capital rate was 10.4%, producing a €246.4 million charge. EBIT after tax plus the disclosed €34.4 million PPA adjustment equaled approximately €191 million, implying an analyst-calculated adjusted post-tax return near 7.9%. The reported EVA was negative €55.4 million. This 7.9% figure is an analytical calculation using the company’s inputs, not a separately disclosed company metric. [S2]

Before DORC, FY2022/23 EVA was positive €134.0 million. In FY2023/24 it fell to positive €8.4 million as average gross capital employed increased to approximately €2.390 billion; in FY2024/25 it became negative. FY2024/25 profitability was inadequate: reported EVA was negative €55.4 million, and an analyst calculation using the company’s framework gives an adjusted post-tax return near 7.9% versus a 10.4% capital charge. [S2][S15]

Company Financials’ standardized ROIC series also declined—from roughly 15.6% in FY2020/21 to 7.2% in FY2024/25—but its balance-sheet and debt conventions do not fully capture the parent-treasury structure. The primary annual report’s EVA is therefore the principal return measure. The independent standardized direction is useful; the exact level is not interchangeable.

Capitalizing research makes the return conclusion more conservative. A simplified five-year straight-line treatment of expensed R&D creates an estimated unamortized research asset near €665 million. Adding back current R&D and deducting modeled amortization produces an estimated post-tax research-adjusted return around 6–7% on more than €3.0 billion of economic capital. This is an analyst estimate sensitive to useful life, attrition and potential overlap with capitalized development. Its message is robust: accumulated research investment does not rescue current ROIC.

Cash-flow quality is mixed. FY2024/25 operating cash flow of €209.9 million exceeded consolidated profit of €142.3 million. Cash additions to property, plant and equipment were €39.4 million and intangible additions €37.2 million, producing conventional CFO-less-capex free cash flow of €133.3 million. Management reported €203.7 million under a different treasury-based free-cash-flow definition. Both may be internally consistent, but they answer different questions. [S2]

Cash conversion exceeded net income in FY2024/25, but receivables absorbed €106.5 million and conventional CFO less tangible and intangible capex was approximately €133 million, materially below the company-defined €203.7 million. [S2]

Nine-month FY2025/26 operating cash flow improved to €145.8 million from €65.7 million as receivables were collected. Net financial debt improved to €234.8 million from €276.9 million at September 2025. That is useful deleveraging evidence, but working-capital release is not equivalent to recurring operating profit. [S1]

Working capital remains material. FY2024/25 inventory was approximately €497 million, more than 22% of revenue, and trade plus related-party receivables were large. Standardized calculations place the cash-conversion cycle near 145 days and inventory days near 179, improved from FY2023/24 but above early-period levels. Inventory carries particular risk during platform transitions, tender losses and product withdrawals.

Reported tangible and intangible capex was €76.6 million, only 3.4% of FY2024/25 revenue, but economic capital intensity is much higher after €326.3 million of expensed R&D, €34.9 million of capitalized development, working capital, leases and acquisitions are included. [S2]

Accounting conservatism is mixed. Expensing most research is conservative. Capitalized development, acquired intangibles, goodwill and repeated non-GAAP exclusions reduce that comfort. Goodwill of €969.7 million and other intangibles of €662.9 million represented almost half of assets. Unfinished development assets and impairment history show that capitalized projects can become stranded. Accounting is conservative in expensing most R&D, but the scale of acquired intangibles, development capitalization and adjustment categories means IFRS and adjusted earnings both require economic normalization. [S1][S2]

The expected approximately €150 million goodwill impairment is noncash and will not itself reduce liquidity. It remains economically informative. The FY2024/25 annual test recorded no impairment, yet by August 2026 management expected a large Ophthalmology charge, indicating that cash-flow expectations deteriorated rapidly or earlier headroom was limited. Management indicated that Iantech-related assets were a major contributor, but final cash-generating-unit allocation was not available at the cutoff. [S1][S2][S3]

Material obligations include €132.5 million of recognized lease liabilities, contingent acquisition consideration, a €400 million parent loan and rising related-party rent and service charges; parent-treasury access reduces immediate refinancing risk but concentrates governance dependency. [S2][S9][S15]

The €400 million parent loan carries a 3.66% fixed rate and a three-year maturity from April 2024. Company net financial debt includes parent treasury receivables, payables and the loan but excludes lease liabilities. Liquidity risk is not acute: FY2024/25 equity was €2.128 billion, the equity ratio was 62.5%, and nine-month cash generation reduced net debt. The primary risk is inadequate return on capital, not immediate insolvency.

Verdict: Financial quality has fallen from excellent to mixed. Cash generation and leverage remain serviceable, but margins, research-adjusted returns and EVA show that recent growth and acquisition spending have not created adequate value.

Capital Allocation

Capital allocation since 2023 combines heavy acquisition spending, an ill-timed repurchase, continued R&D and a reduced dividend. The pivotal transaction was DORC. Control transferred on 3 April 2024. Total consideration was €1.024 billion, comprising €709.6 million of fixed consideration and repayment of €314.1 million of external financing. Net acquisition cash outflow was €1.006 billion after acquired cash. [S15]

Purchase accounting identified €468.7 million of intangible assets and €581.6 million of goodwill. DORC contributed €99.9 million of revenue and an €8.8 million consolidated loss between closing and September 2024, including purchase-accounting effects. The annual report’s pro forma group figures are not evidence of steady-state return because they do not establish integration cost, capital allocation or future margin. [S15]

The strategic rationale is credible. DORC adds retinal consoles, instruments and consumables and makes the group a more complete surgical competitor. The return evidence is unfavorable. Gross capital employed nearly doubled, net liquidity became net debt and EVA turned negative. Platform and site rationalization now seeks to remove duplication. DORC increased strategic scope and procedure-linked revenue, but it has not demonstrated an adequate return: group EVA fell from positive €134 million before closing to negative €55.4 million in FY2024/25 as the capital base expanded. [S2][S15]

That conclusion is group-level, not an asset-level accusation. China and legacy operations also weakened, and DORC may require several years to mature. The necessary missing disclosure is a bridge from DORC revenue to recurring gross profit, operating cash contribution, acquisition and restructuring capital, and incremental EVA.

Iantech presents clearer evidence of failure. The company recorded impairments in FY2023/24 and FY2024/25, then additional R&D impairment in FY2025/26 and expected a much larger goodwill charge. Katalyst activities are also being wound down where portfolios overlap DORC. These outcomes challenge the prior appearance of consistently disciplined medical-device M&A. [S1][S2][S3]

The issuer’s FY2023/24 buyback acquired 1,904,491 shares, or 2.1293% of issued capital, for €150.1 million at an average €78.76. At €30.30 those treasury shares were worth approximately €57.7 million, a mark-to-market shortfall near €92 million. That calculation does not prove permanent loss if the stock later recovers, but it is valid evidence about timing and price discipline. The issuer repurchased shares at €78.76 on average, more than twice the latest price, and reduced economically outstanding shares by only 2.1%; the shares remain in treasury. [S2][S23]

Carl Zeiss AG’s 2026 announcement is economically different. The parent may purchase up to €200 million in the market through February 2027 while keeping voting rights below 70%. It said the program would be independently executed and that it did not then intend a domination agreement or delisting. The program transfers ownership among shareholders; it does not use issuer cash or reduce issued shares. It is a signaling and float event, not issuer capital return, and the phrase up to does not guarantee the full amount will be purchased. [S6]

Insider activity is modestly positive. Supervisory Board chair Peter Kameritsch purchased 2,000 shares at €25.90 for €51,800. CFO Justus Wehmer purchased approximately €103,568 at an average €32.365. Interim CEO Andreas Pecher purchased €20,237.60 at €30.85. These were disclosed open-market purchases, not grants, exercises or tax-withholding transactions. Their aggregate size is too small to establish intrinsic value, but they provide better alignment evidence than compensation awards. [S10][S11][S12]

Management compensation has no share-based component, and no material insider stock issuance or option dilution is evident; this protects the share count but provides less automatic ownership alignment. [S2][S25]

The dividend policy targets roughly one-third of parent-company profit. Dividend per share declined from €1.10 for FY2022/23 to €0.60 for FY2023/24 and €0.55 for FY2024/25. The latest proposed distribution was approximately €48.1 million on 87.536 million dividend-bearing shares, covered by €133.3 million of conventional FY2024/25 free cash flow. The dividend targets roughly one-third of parent profit and remains cash-covered, but the reduction from €1.10 to €0.55 shows that it is not a stable-income commitment. [S2]

FY2024/25 conventional free cash flow was approximately €133 million; it covered the €48 million proposed dividend and supported deleveraging, while current priorities are restructuring, product development and repairing returns on the DORC-enlarged capital base. [S1][S2]

Executive variable pay uses cash short-term and three-year long-term incentives. Metrics include Meditec EVA, Meditec free cash flow and ZEISS-group EVA, with malus and clawback provisions. Maximum annual remuneration is €3.0 million for the CEO and €1.75 million for other board members. Variable compensation is paid in cash and uses EVA and company-defined free cash flow, with three-year LTI mechanics and malus or clawback provisions; it contains no equity component. [S25]

Some reported payouts related to prior performance periods: former CEO Markus Weber’s STI achievement was 147% and CFO Wehmer’s 168%. Timing explains part of the apparent mismatch with later negative EVA, but opaque thresholds and group-level metrics reduce minority-shareholder transparency. The 2026 AGM approved the remuneration report with 82.06% support, leaving 17.94% opposed. [S16][S25]

Management’s incentives nominally reward value creation, but high prior-period cash payouts, forecast failures and the acquisition-plus-buyback sequence imply that operational ambition has at times outrun per-share return discipline. [S2][S13][S15][S25]

Verdict: The balance sheet can absorb prior mistakes, but capital allocation has destroyed material value. Credibility requires positive EVA, no large new acquisition before DORC earns its charge, and clear separation between parent purchases and issuer repurchases.

Changes and Headwinds — Last Two Years

The last two years were not one homogeneous downturn. China shifted from a growth engine to several distinct headwinds: national IOL procurement, withdrawal of a bifocal lens, tender timing, refractive-procedure weakness, cautious equipment spending, currency and local competitors. Outside China, North American capital budgets and parts of Asian refractive demand weakened. [S1][S3][S24]

Both external conditions and internal actions drove the reset: China procurement, currency and clinic capital spending were external, while product withdrawals, duplicated platforms, acquisition choices, inventory scrapping and unreliable guidance were internal. [S1][S3][S13][S24]

Guidance history demonstrates the forecasting problem. In June 2024, management cut FY2023/24 expectations after equipment, China refractive consumables and IOL procurement fell short. In December 2025, the initial FY2025/26 outlook contemplated approximately €2.3 billion of revenue and a 12.5% EBITA margin. That outlook was withdrawn in January 2026 after preliminary first-quarter revenue of €467 million and EBITA of only about €8 million. By May, guidance was reset to €2.15–2.20 billion and an 8–10% adjusted-EBITA margin. The range remained in August, but management indicated that recent refractive weakness favored its lower portions. [S1][S3][S5][S13][S24]

The H1 call also illustrates why commentary must be tested. Management expected improving organic momentum in the third quarter. Formal nine-month revenue still declined 2.9% reported, with Ophthalmology down 4.8%, although the broad currency-adjusted group measure stabilized. The prediction was partly supported by sequential improvement, but not by a clean organic rebound. [S1][S4]

Leadership changed repeatedly. Markus Weber left the CEO role in 2025. Maximilian Foerst became CEO and then departed at year-end after the Supervisory Board identified a code-of-conduct violation involving a conflict of interest with a person in his working environment; the company said the matter was not business-related. Andreas Pecher became interim CEO on 1 January 2026. Bronwyn Brophy O’Connor was appointed future CEO in May, but her exact start date remained undisclosed at the cutoff. [S7][S8]

ProfitUp is restructuring the portfolio and footprint. Anterior and posterior surgery are being consolidated; QUATERA is being sunset in favor of EVA NEXUS; overlapping Katalyst activities are being wound down; handpiece work is moving; a future India manufacturing presence is planned; and China operations are being localized. Up to 1,000 positions may be affected. These actions can remove cost, but they increase employee-retention, launch, service and quality risk during transition. [S3][S5]

Important changes include DORC integration, consolidation of surgical platforms, the Katalyst wind-down, planned India production, a larger China footprint, a new Ophthalmology leader and an incoming permanent CEO. [S3][S5][S7]

Related-party economics are also changing. New arrangements increase annual Jena rent from approximately €2 million in FY2024/25 toward €10 million from FY2027/28 and raise shared-service costs by approximately €30 million through FY2028/29. These costs form much of the €40 million infrastructure offset within ProfitUp. Because the controlling parent is counterparty, independent benchmarking matters. [S5][S9]

No thesis-changing IFRS policy change was identified; comparability deteriorated instead because acquisition accounting, changing EBITA adjustments, tariff refunds, impairments and a nonstandard free-cash-flow definition became more material. [S1][S2]

The operating environment changed materially through China procurement, weaker equipment and refractive demand, currency and local competition, while the company’s portfolio complexity amplified the effect. [S1][S3][S22]

Verdict: The deterioration was neither purely cyclical nor purely self-inflicted. External shocks exposed weaknesses in forecasting, portfolio design and capital allocation, prompting a broad leadership and operating reset.

Risk Analysis

The principal stock-decline factors are further guidance cuts, China access or pricing losses, weak capital orders, failed restructuring, product-quality events, delayed approvals, adverse currency and evidence that DORC cannot earn its capital charge. [S1][S3][S13][S15]

China risk is not one variable. IOL tender access affects price and volume; refractive utilization affects pack demand; equipment caution affects future installed base; local competition affects placements; and currency affects translation and channel invoicing. A model that applies a single China revenue haircut can miss a disproportionate gross-profit effect.

ProfitUp creates execution risk on both sides of the income statement. Headcount and site reductions can produce savings, but disruption can delay approvals, weaken service or lose revenue. Cash implementation cost can also increase debt temporarily even when adjusted EBITA improves. The announced €150 million ceiling should therefore be monitored against cash, not only adjusted exclusions.

Backlog provides limited protection. The €432 million order backlog exceeded the fiscal-year opening balance, but its product composition, age, cancellation rights and regulatory dependencies are not fully disclosed. Backlog is evidence of demand, not equivalent to revenue or cash.

Parent dependency reduces acute financing risk but creates governance concentration. The parent loan and treasury system give access to liquidity, while the parent also controls votes, receives service and rental payments and handles a material portion of sales. Minority investors need arm’s-length economics, not merely parent support.

A catastrophic investment loss would require several failures together: permanent erosion of SMILE or microscopy leadership, major product-liability or regulatory sanctions, collapse of China access, unsuccessful restructuring and loss of parent-supported liquidity. [S1][S2][S17]

A total-loss path is remote and would most plausibly require fraud, crippling liability, broad regulatory exclusion or a governance and liquidity event that destroys the operating franchises; ordinary recession or one failed product is insufficient. [S1][S2]

The more realistic severe outcome is not bankruptcy but persistent single-digit margins and a further 30–50% equity decline. Low leverage and positive cash flow provide survival capacity, while negative EVA makes permanent capital loss plausible even without financial distress.

Verdict: Solvency risk is low, but recovery-dependent valuation creates meaningful permanent-capital-loss risk. The dominant exposures are margin, China and franchise monetization rather than leverage.

Valuation Discussion

The 11 September 2026 Xetra close was €30.30. Multiplying by 87.536 million economically outstanding shares gives equity value of approximately €2.65 billion. The headline value using all 89.441 million issued shares would be about €2.71 billion, but treasury shares should be excluded from the economic share count. [S2][S23]

June 2026 net financial debt was €234.8 million, producing simplified enterprise value of approximately €2.89 billion. The company’s net-debt definition does not include reported lease liabilities. Adding €132.5 million of latest fully disclosed leases yields approximately €3.02 billion before small minority interests. Both definitions are shown because peer data can differ in lease treatment. [S1][S2]

Management’s FY2025/26 guidance implies adjusted EBITA of €172–220 million. Simplified enterprise value is therefore approximately 13.1–16.8 times adjusted EBITA, with 14.7 times at the midpoint. Lease-adjusted enterprise value implies about 13.8–17.6 times and 15.4 times at the midpoint. Simplified EV/revenue is approximately 1.33 times midpoint guidance; lease-adjusted EV/revenue approximately 1.39 times.

FY2024/25 metrics are less useful because profitability deteriorated after year-end. Simplified EV/FY2024/25 EBITA is approximately 11.2 times, and equity value/attributable net income about 18.8 times. Conventional FY2024/25 free-cash-flow yield is approximately 5.0%. Reported FY2025/26 P/E will be distorted by the expected goodwill impairment.

Peer comparisons require matching business mix and accounting:

Alcon’s sales premium is rational in part. It generated US$5.751 billion of Surgical revenue in 2025, grew consumables 6%, launched UNITY and possesses much greater surgical scale. Bausch + Lomb’s lower multiple reflects leverage and mixed profitability. Carl Zeiss Meditec’s sales discount does not automatically imply undervaluation because current sales convert poorly into profit.

Historical multiples are also hazardous. The share price is far below its historical peak, but DORC changed enterprise value and the earnings denominator collapsed. Any historical-percentile argument must be recomputed using current debt, leases, shares and profit. The earlier need for a pro forma acquisition bridge is now stale because DORC’s assets and financing are reflected in reported accounts; acquisition-adjusted return analysis remains necessary. [S1][S2][S15][S23]

The current quotation appears to embed three expectations: adjusted margin recovers toward approximately 11–12%; the company absorbs restructuring cash without balance-sheet stress; and core SMILE, diagnostics and microscopy positions remain intact. It does not capitalize a full return to historical 20%-plus EBIT margins. It also does not price permanent 8% margins as a certainty.

The following FY2028/29 scenarios are analyst estimates. Values are discounted three years at 10%; net-obligation assumptions include net financial debt and leases, and no material share dilution is assumed.

The persistent-impairment case assumes China weakness extends beyond IOLs, product exits constrain revenue, ProfitUp is substantially consumed by infrastructure and stranded cost, and the business receives a capital-goods multiple. A 9.5% margin remains below the capital charge and warrants no premium.

The partial-repair case assumes mid-single-digit recovery from the FY2025/26 base, most of the €160 million stated net opportunity is realized by FY2028/29, but gross margin and China do not fully return to historical conditions. Fourteen percent remains below management’s historical 20%-plus aspiration yet is sufficient to restore positive economic profit.

The successful case requires China stabilization, strong procedure attachment, DORC cross-selling, limited restructuring leakage and a 16.5% margin. It assumes the surviving installed-base economics deserve a premium but does not require the old peak margin.

The market is correct to discount old margins, procurement risk, DORC integration and gross-versus-net savings. It may be too pessimistic if proprietary packs remain resilient and the large duplicated cost base can be removed without revenue damage. The fragile bull assumptions are stable SMILE economics, successful EVA NEXUS adoption, service continuity and leadership discipline. The fragile bear assumptions are that an 8–10% margin remains permanent despite identifiable duplication and that the installed base produces no operating leverage.

Valuation sensitivity is dominated by terminal margin, not revenue. Every 100 basis points of EBITA margin on €2.5 billion of sales equals €25 million of EBITA. At a 13-times multiple, that changes terminal enterprise value by €325 million, or roughly €3.70 per current share before discounting. This makes quarterly evidence on net savings and gross margin more important than small changes in reported revenue.

Verdict: The shares offer meaningful recovery optionality but are not an obvious statistical bargain. Persistent single-digit margins imply severe downside, while a 14–16.5% margin creates material value; the present price sits between those outcomes.

Variant Perception

The apparent consensus is that Carl Zeiss Meditec owns strong technology but faces a prolonged earnings repair. The shares no longer carry the valuation of a dependable high-margin compounder. That broad view is reasonable; the variant question is whether current disruption is temporary mismanagement of a durable installed base or evidence that the former economics were never durable.

The strongest bull case is that the market is valuing a rare set of installed-base assets as an ordinary capital-goods vendor. Approximately half of revenue is recurring or procedure-linked, SMILE has documented proprietary packs and licenses, microscopy retains management-estimated leadership, order backlog is €432 million, and balance-sheet leverage is modest. ProfitUp’s stated net improvement is large relative to current EBITA. A permanent CEO can impose portfolio and capital discipline without rebuilding the technology base. [S1][S3][S5][S17]

The strongest bear case is that technology quality concealed deteriorating allocation discipline. Revenue growth since FY2020/21 coincided with lower EBIT. DORC and the issuer buyback consumed more than €1.15 billion before the latest profit collapse. China procurement structurally reduces premium pricing, Alcon has greater scale, diagnostics are interoperable, and the gross restructuring target may be absorbed by new infrastructure costs, inflation and lost revenue. On that reading, historical margins above 20% reflected a favorable mix and underinvested cost base rather than a sustainable group norm. [S2][S9][S15][S18][S20]

Thoughtful investors have focused on the FY2026/27 margin bridge, ProfitUp phasing, China refractive procedures and IOL procurement, DORC synergies, infrastructure costs and whether parent purchases should be treated as capital return. Management’s answers were cautious: FY2026/27 is a consolidation year, savings are back-end loaded, China IOL recovery depends on a tender, and commercial DORC synergies should become more visible later. [S3][S4]

The load-bearing assumptions are:

1. Installed-base productivity. The bull case requires procedures, consumables and service to grow after systems are placed. It is falsified by declining recurring gross profit and procedures per installed unit despite stable placements. The bear case is weakened by four quarters of accelerating pack utilization and service attachment.
2. Net ProfitUp savings. The bull case requires gross savings to exceed infrastructure, stranded and implementation costs. It is falsified if cumulative cash cost exceeds €150 million materially or the €40 million annual offset grows. The bear case is weakened by at least €100 million of visible annualized net savings without service or revenue deterioration.
3. Containable China pressure. The bull case assumes procurement damage remains concentrated in IOLs and refractive-pack pricing holds. It is falsified if local competitors take material VISUMAX placements or pack price declines. The bear case is weakened by successor-lens tender access, stable pack price and renewed procedure growth.
4. DORC return. The bull case requires recurring retinal contribution sufficient to earn the acquisition capital charge. It is falsified if EVA remains negative after restructuring despite DORC growth. The bear case is weakened by disclosed incremental cash returns and positive group EVA.
5. Leadership discipline. The bull case requires conservative guidance and no major acquisition before returns recover. Another withdrawal, unexplained turnover or large deal would falsify it. Several periods of reliable guidance and transparent capital-return thresholds would weaken the bear view.

The factor model snapshot was unavailable. Statistical factor exposures and alpha therefore cannot be reported, and no industry classification should be inferred from an absent model. The event map suggests high sensitivity to company guidance, but that is not a formal residual-return estimate. Parent purchases may affect float and technical supply-demand independently of fundamental value. [S6][S23]

The differentiated view is not that the moat vanished. It is that the market is correctly demanding evidence that the moat can earn a return after research, acquisitions and restructuring. Upside comes from translating installed-base quality into post-investment cash returns, not from restating market-share claims.

Verdict: The market may underprice a successful repair, but skepticism is rational after repeated forecast and allocation failures. The variant thesis becomes investable only when operating evidence separates temporary complexity from structural margin loss.

Fact vs. Interpretation

The central contradiction is between the quality narrative and the return record. Market positions, patents, installed systems and recurring revenue are supported facts or identified management estimates. Falling gross margin, negative EVA and forecast failures are also facts. The correct synthesis is to require intangible advantages to reappear in cash returns.

Verdict: Reported evidence establishes franchise strength and financial deterioration simultaneously. Recovery claims remain hypotheses until savings, attachment economics and EVA are disclosed.

Open Questions

• When will Bronwyn Brophy O’Connor begin as CEO, and which capital-allocation decisions require her approval before then? [S7]
• What are annual ProfitUp gross savings, infrastructure expense, stranded costs, cash charges and revenue losses by workstream? [S3][S5]
• How much of the €432 million backlog is equipment, how old is it and what portion is cancellable? [S1]
• When will the successor bifocal IOL enter China procurement, at what realized price, and how much lost gross profit can return? [S3][S22]
• What are VISUMAX procedures, treatment-pack price and revenue per installed system by geography? [S3][S17]
• What revenue, recurring gross profit, operating cash contribution and capital employed are directly attributable to DORC? [S15]
• How will the expected impairment be allocated among Iantech, DORC and other cash-generating units? [S1][S3]
• What independent benchmark supports the higher related-party rent and service charges? [S9]
• What parent treasury capacity is contractually available, on what terms and for how long? [S2][S15]
• Will the revised remuneration framework add equity ownership, transparent EVA thresholds or relative-return measures? [S16][S25]
• Which products and development programs will be exited, and what revenue, service or impairment follows? [S3][S5]
• Why do standardized and broader currency-adjusted growth descriptions differ, and will management provide a permanent reconciliation? [S1]

What Must Be True

Bull tests

• Organic revenue must return to at least mid-single-digit growth without acquisition support. Reported, currency-adjusted and acquisition-adjusted results should be reconciled rather than mixed. FY2024/25 organic and currency-adjusted growth was only 3.3%, and nine-month FY2025/26 reported revenue declined 2.9%. [S1][S2]
• Adjusted EBITA margin must rise above 12% and then toward the mid-teens, with volume, price, mix, gross savings, infrastructure expense and one-offs disclosed separately. The current comparator is 8.0%, not the historical 20%-plus peak. [S1][S5]
• Conventional CFO less tangible and intangible capex must cover restructuring cash, dividends and debt reduction over a rolling year. FY2024/25 conventional free cash flow was approximately €133 million. [S2]
• China refractive-pack price and utilization must remain stable, and the successor IOL must regain tender access without eliminating its contribution margin. The existing evidence is management’s no-current-pack-pressure statement and externally verified severe IOL procurement pricing. [S3][S22]
• DORC and EVA NEXUS must produce recurring contribution and positive incremental EVA after acquisition, development and restructuring capital. The current evidence is a €1.024 billion purchase followed by negative group EVA. [S2][S15]
• Product-quality costs, scrapping and development impairments must normalize. Nine-month adjustments included IOL scrapping and R&D impairment. [S1]
• The permanent CEO must issue conservative guidance and avoid major M&A until EVA is positive. Recent guidance withdrawals and executive turnover make this a measurable governance test. [S7][S8][S13]

The bull thesis is falsified if any two of the following persist for four quarters: organic growth below 3%; adjusted EBITA margin below 10%; negative conventional free cash flow after restructuring; declining recurring gross profit; another material impairment; or another guidance withdrawal.

Bear tests

• China pressure must spread from IOL procurement into refractive price, utilization or platform share. Stable pack price and accelerating procedures would contradict this premise. [S3][S17]
• ProfitUp savings must be substantially consumed by the €40 million infrastructure step-up, implementation cost, inflation and revenue exits. A disclosed annualized net benefit above €100 million without service deterioration would contradict it. [S5][S9]
• DORC cross-selling must remain insufficient to earn the acquisition capital charge. Disclosed positive asset-level cash returns or sustained positive group EVA would contradict it. [S2][S15]
• Microsurgery must lose share or remain structurally below prior margins despite the KINEVO cycle. Currency-adjusted nine-month growth of 7.1% and modest margin improvement are early counterevidence. [S1]
• The market must continue valuing the company as a slow-growth equipment vendor despite proprietary SMILE consumables. Stable pack economics and stronger recurring gross profit would weaken that premise. [S1][S17]

The bear thesis is falsified if organic revenue exceeds 5%, adjusted EBITA exceeds 12%, conventional free cash flow exceeds €175 million and EVA turns positive within the same rolling year, reinforced by verified China tender recovery and disclosed DORC returns.

The decisive condition is that the surviving moat must earn a return on all capital already committed—not merely produce higher adjusted EBITA before restructuring and acquisition costs. The principal evidence is available in the nine-month report, FY2024/25 annual report, latest management transcript and Alcon peer filing.

Public source appendix

• S1: Carl Zeiss Meditec — Interim Report, Nine Months FY2025/26 — primary interim report; published 2026-08-06; pp. 1–9: revenue, segment results, recurring mix, adjustments, cash flow, net debt, guidance and expected impairment
• S2: Carl Zeiss Meditec Annual Report 2024/25 — primary annual report; published 2025-12-09; pp. 13–32, 40–50, 64–111 and 122: business, markets, financial statements, EVA, R&D, debt, leases, related parties and ownership
• S3: Carl Zeiss Meditec Nine-Month FY2025/26 Analyst Conference Transcript — primary management transcript; published 2026-08-06; pp. 1–17: China, ProfitUp, product rationalization, DORC, guidance and investor questions
• S4: Carl Zeiss Meditec Half-Year FY2025/26 Conference Transcript — primary management transcript; published 2026-05-12; pp. 1–29: H1 performance, guidance reset, China, DORC and investor questions
• S5: Carl Zeiss Meditec Half-Year FY2025/26 Results and ProfitUp — primary company release; published 2026-05-12; H1 results, FY2025/26 outlook, ProfitUp targets, implementation envelope and affected positions
• S6: Carl Zeiss AG Plans to Increase Meditec Shareholding — primary controlling-shareholder release; published 2026-06-22; Potential purchase amount, execution period, voting-right ceiling and stated intentions
• S7: Appointment of Bronwyn Brophy O’Connor as Future CEO — primary company release; published 2026-05-22; Future CEO appointment, background and unspecified start timing
• S8: Departure of CEO Maximilian Foerst — primary company release; published 2025-12-08; Departure, code-of-conduct finding and interim leadership
• S9: Carl Zeiss Meditec Related-Party Agreement with Carl Zeiss AG — regulated related-party disclosure; published 2026-05-12; Jena lease and shared-service cost increases
• S10: Director’s Dealing — Andreas Pecher Purchase — regulated transaction disclosure; published 2026-09-10; Transaction date, venue, average price and aggregate value
• S11: Director’s Dealing — Justus Wehmer Purchase — regulated transaction disclosure; published 2026-09-04; Transaction date, venue, average price and aggregate value
• S12: Director’s Dealing — Peter Kameritsch Purchase — regulated transaction disclosure; published 2026-05-28; 2,000-share purchase at €25.90
• S13: Carl Zeiss Meditec Withdraws FY2025/26 Guidance After Preliminary Q1 Results — primary inside-information release; published 2026-01-22; Preliminary Q1 revenue and EBITA and withdrawal of prior guidance
• S14: Carl Zeiss Meditec ESCRS 2026 Product Announcements — primary product release; published 2026-09-03; EVA NEXUS, AT LUCIA toric, Surgery Planner and VISUMAX product updates and regulatory caveats
• S15: Carl Zeiss Meditec Annual Report 2023/24 — primary annual report; published 2024-12-11; pp. 64–68 and 83–84: financial statements, DORC purchase accounting, parent loan and buyback
• S16: Carl Zeiss Meditec 2026 AGM Voting Results — primary AGM record; published 2026-03-26; Remuneration-report vote and board resolutions
• S17: FDA Professional Use Information — VISUMAX SMILE — primary regulator labeling; publication date unavailable; pp. 3–7 and 40–48: training, treatment license, single-use packs and approved-pack restrictions
• S18: Alcon 2025 Form 20-F — primary peer filing; published 2026-02-10; Item 4.B and operating review: surgical market, installed base, UNITY platforms and 2025 segment revenue
• S19: Bausch + Lomb 2025 Form 10-K — primary peer filing; published 2026-02-18; Business and MD&A: Surgical portfolio, revenue mix, segment revenue, recall and profit
• S20: Topcon Harmony Clinical Data Management — primary competitor product evidence; publication date unavailable; Vendor-inclusive interoperability, multi-device connectivity and data-export functionality
• S21: WHO World Report on Vision — authoritative industry evidence; published 2019-10-08; pp. 59–60 and 94–95: myopia projections, aging, cataract and unmet eye-care demand
• S22: China National Healthcare Security Administration — IOL Procurement and Eye-Care Policy — primary government policy evidence; published 2024-11-24; National high-value-consumables procurement round and average IOL price reductions
• S23: Company Financials and Deutsche Börse — AFX.XETRA Daily Price History — primary exchange and standardized market-data cross-check; publication date unavailable; Split-adjusted Xetra daily closes from 10 September 2021 through 11 September 2026; exchange-qualified symbol XETR:AFX
• S24: Carl Zeiss Meditec June 2024 Revenue and EBIT Guidance Reduction — primary inside-information release; published 2024-06-17; Eight-month preliminary performance, equipment weakness, China headwinds and reduced FY2023/24 outlook
• S25: Carl Zeiss Meditec Remuneration Report 2024/25 — primary remuneration report; published 2025-12-09; Fixed pay, STI, LTI, EVA and free-cash-flow metrics, maximum remuneration and individual outcomes